Pharmaceuticals as Workplace Hazards


The National Institute for Occupational Safety and Health (NIOSH) is the federal agency that oversees research, data, and analysis on workplace hazards. They have looked into hazardous drugs that healthcare workers may be exposed to and categorized these compounds into three groups. Group 1 is antineoplastic drugs (roughly, chemotherapy medications). Group 2 is other drugs (not antineoplastic) that are hazardous, while Group 3 are drugs that may interrupt fertility in women or men or that may get into breast milk.

Group 1

Group 1

ado-trastuzumab emtansine
afatinib
altretamine
amsacrine
anastrozole
arsenic trioxide
axitinib
azacitidine
Bacillus Calmette Guerin (BCG)
belinostat
bendamustine
bexarotene
bicalutimide
bleomycin
bortezomib
bosutinib
brentuximab vedotin
busulfan
cabozantinib
capecitabine
carfilzomib
carboplatin
carmustine
chlorambucil
cisplatin
cladribine
clofarabine
crizotinib
cyclophosphamide
cytarabine
dabrafenib
dacarbazine
dactinomycin
dasatinib
daunorubicin
decitabine
degarelix
docetaxel
doxorubicin
enfortumab vedotin
enzalutamide
epirubicin
eribulin
erlotinib
estramustine
etoposide
everolimus
exemestane
floxuridine
fludarabine
fluorouracil
flutamide
fulvestrant
gemcitabine
gemtuzumab ozogamicin
goserelin
histrelin
hydroxyurea
idarubicin
ifosfamide
imatinib
inotuzumab ozogamicin
irinotecan
ixazomib
ixabepilone
letrozole
leuprolide
lomustine
mechlorethamine
megestrol
melphalan
mercaptopurine
methotrexate
mitomycin
mitotane
mitoxantrone
nelarabine
nilotinib
omacetaxine
oxaliplatin
paclitaxel
panobinostat
pazopanib
pemetrexed
pentostatin
pertuzumab
pipobroman
polatuzumab vedotin
pomalidomide
ponatinib
pralatrexate
procarbazine
regorafenib
romidepsin
sacituzumab govitecan
sorafenib
streptozocin
sunitinib
tamoxifen
temozolomide
temsirolimus
teniposide
thioguanine
thiotepa
topotecan
trabectedin
trametinib
trastuzumab deruxtecan
trifluridine/tipiracil (combination only)
triptorelin
valrubicin
vandetanib
vemurafenib
vinblastine
vincristine
vinorelbine
vismodegib
vorinostat
ziv-aflibercept

technician preparing chemotherapy

Group 2

abacavir
alefacept
apomorphine
azathioprine
carbamazepine
chloramphenicol
cidofovir
cyclosporine
deferiprone
dexrazoxane
diethylstilbestrol
divalproex
entecavir
estradiol
estrogen/ progesterone combinations
estrogens, conjugated
estrogens, esterified
estropipate
fingolimod
fluoxymesterone
fosphenytoin
ganciclovir
leflunomide
lenalidomide
liraglutide recombinant
medroxyprogesterone acetate
methimazole
mipomersen
mycophenolate mofetil
mycophenolic acid
nevirapine
ospemifene
oxcarbazepine
palifermin
phenoxybenzamine
phenytoin
pipobroman
progesterone
progestins
propylthiouracil
raloxifene
rasagiline
sirolimus
spironolactone
tacrolimus
teriflunomide
thalidomide
tofacitinib
uracil
valganciclovir
zidovudine

Group 3

acitretin
alitretinoin
ambrisentan
bosentan
cabergoline
cetrorelix
choriogonadotropin
clomiphene
clonazepam
colchicine
dinoprostone
dronedarone
dutasteride
eslicarbazepine
ergonovine/methylergonovine
finasteride
fluconazole
ganirelix
gonadotropin, chorionic
icatibant
lomitapide
macitentan
mentropins
methyltestosterone
mifepristone
misoprostol
nafarelin
oxytocin
pamidronate
paroxetine
pasireotide
pentetate calcium trisodium
peginesatide
plerixafor
ribavirin
riociguat
temazepam
testosterone
topiramate
tretinoin
ulipristal
valproate/valproic acid
vigabatrin
voriconazole
warfarin
ziprasidone
zoledronic acid
zonisamide